Appendix 4E and Annual Report to Shareholders 2026

Key points

• Revenue decreased by 1% to $94,024,398
• Profit from ordinary activities before tax decreased by 8%
• Net profit decreased by 6%

Full summary

Clinuvel Pharmaceuticals Ltd. reported its financial results for the year ended June 2026, showing a 1% decrease in revenues to $94,024,398, an 8% decrease in profit from ordinary activities before tax to $47,659,765, and a 6% decrease in net profit to $33,916,819. The company declared a fully franked final dividend of $0.05 per ordinary share, payable on September 18, 2026. The company's focus on North America, particularly the U.S., is highlighted as a key strategy for future growth, with significant expansion plans in place.

Guidance

Revenue: $94,024,398; Profit before tax: $47,659,765; Net profit: $33,916,819

Outlook

Clinuvel Pharmaceuticals Ltd. plans to increase its presence in North America, particularly the U.S., by expanding its team and network of Specialty Centers, building self-manufacturing capability, and potentially listing on the Nasdaq Stock Market.